News

An estimated 1.2 million Americans are discharged from a hospital with a diagnosis of acute coronary syndrome (ACS) each year. Now, a new randomized controlled trial dubbed "ATLAS ACS 2" (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary Syndrome), is suggesting rivaroxaban may reduce the risk of the composite end point of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent ACS, but at a cost of increased major bleeding.

In patients with major depressive disorder (MDD) and general medical conditions, the use of antidepressants was safe and effective compared to patients without such conditions. Combination therapy was no different than monotherapy, regardless of the number of comorbidities present, according to the recent findings of a new randomized, single-blind, placebo-controlled trial published in The Annals of Family Medicine.

Recent FDA action (through January 2012) related to dapagliflozin, progesterone vaginal gel 8%, ACH-1625 protease inhibitor, CPP-115 GABA aminotransferase inhibitor, AC607, NBI-98854 VMAT2 inhibitor, AIC246 inhibitor, CBP501, Porfimer sodium, inhaled nitric oxide, carbamazepine extended-release capsules, levetiracetam extended-release tablets

The healthcare overhaul has allowed 2.5 million young adults to gain insurance coverage under their parents' plans, a figure that is more than double previous estimates.

New Distribution Trend

Health Care Service Corporation offers defined-contribution plans in a private-exchange model.

In administrating Commonwealth Care, the Massachusetts' Connector has been hugely successful in enrolling people in subsidized health plans. As of last August, nearly 40,000 people had used the Connector to purchase Commonwealth plans.

According to experts, improving accessibility to laboratory tests and results improves patient engagement in their health and could have significant cost saving implications for managed care.

GOP candidate Mitt Romney argues that his proposal to convert Medicare from a defined-benefit program to a defined-contribution program will rescue Medicare by creating competition among plans and drive down costs. Republican Paul Ryan and Democratic Senator Ron Wyden have a similar proposal.

FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days.

FDA and Seattle Genetics, which makes brentuximab vedotin (Adcetris), have updated the warning label on the company’s cancer drug after a second patient developed progressive multifocal leukoencephalopathy.

Older women who use statins may be at an increased risk for diabetes mellitus, according to the results of a study published online January 9, in the Archives of Internal Medicine.

Approximately 1 in 100 patients undergoing total or partial knee replacement surgery and 1 in 200 patients undergoing total or partial hip replacement surgery will experience a venous thromboembolism event, including deep vein thrombosis and pulmonary embolism, before being discharged from the hospital, according to a new study.